These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39769)

  • 1. Changes in dopamine-mediated behaviour during one year's neuroleptic administration.
    Clow A; Jenner P; Marsden CD
    Eur J Pharmacol; 1979 Aug; 57(4):365-75. PubMed ID: 39769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):135-44. PubMed ID: 6103813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Adv Biochem Psychopharmacol; 1980; 24():335-40. PubMed ID: 7190762
    [No Abstract]   [Full Text] [Related]  

  • 5. Interpretation of changes in apomorphine-induced stereotyped behaviour in rats receiving continuous administration of trifluorperazine for 15 months.
    Rupniak NM; Boyce S; Jenner P; Marsden CD
    Neuropharmacology; 1984 Aug; 23(8):893-8. PubMed ID: 6148709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential sensitivity to neuroleptic drugs of cerebral dopamine receptors following chronic treatment of rats with trifluoperazine.
    Dawbarn D; Pycock C
    Eur J Pharmacol; 1981 May; 71(2-3):233-45. PubMed ID: 6113967
    [No Abstract]   [Full Text] [Related]  

  • 7. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural effects of chronic treatment with apomorphine in combination with neuroleptic drugs.
    Kenny M; Leonard BE
    J Neurosci Res; 1980; 5(4):291-8. PubMed ID: 6107385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.
    Nohria V
    Methods Find Exp Clin Pharmacol; 1983; 5(6):357-64. PubMed ID: 6137599
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.
    Waddington JL; Gamble SJ
    Eur J Pharmacol; 1980 Oct; 67(4):363-9. PubMed ID: 7192633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.
    Waddington JL; Cross AJ; Gamble SJ; Bourne RC
    Adv Biochem Psychopharmacol; 1983; 37():299-308. PubMed ID: 6138952
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of discontinuous drug administration on the development of dopamine receptor supersensitivity during chronic trifluoperazine or cis-flupenthixol administration to rats.
    Murugaiah K; Theodorou A; Clow A; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1985; 86(1-2):228-32. PubMed ID: 3927361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity.
    Arnt J; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
    Eur J Pharmacol; 1982 Dec; 86(2):185-98. PubMed ID: 6130958
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-opiate beta-endorphin fragments and dopamine--I. The neuroleptic-like gamma-endorphin fragments interfere with the behavioural effects elicited by small doses of apomorphine.
    Van Ree JM; Innemee H; Louwerens JW; Kahn RS; De Wied D
    Neuropharmacology; 1982 Nov; 21(11):1095-101. PubMed ID: 6184639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
    Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
    Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioural and biochemical changes following chronic administration of L-dopa to rats.
    Pycock C; Dawbarn D; O'Shaughnessy C
    Eur J Pharmacol; 1982 Apr; 79(3-4):201-15. PubMed ID: 7201400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some behavioural effects of chloroquine in rats suggesting dopaminergic activation.
    Amabeoku GJ
    Indian J Med Res; 1994 Feb; 99():87-94. PubMed ID: 8005645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1980; 69(3):227-33. PubMed ID: 6774362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.